Race Oncology (ASX:RAC) Announces Safe Dosing of First Patient in Phase 1 RC220 Trial
Race Oncology (ASX:RAC) successfully dosed the first patient in the Phase 1 RC220 trial for advanced solid tumours, marking a key milestone.
Race Oncology Ltd
Race Oncology (ASX:RAC) successfully dosed the first patient in the Phase 1 RC220 trial for advanced solid tumours, marking a key milestone.
Race Oncology (ASX:RAC) initiates its first Australian clinical site for the Phase 1 RC220 trial, marking a significant step in advancing cancer treatment.